Overview

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from multiple clinical trials of nebokitug, including the Phase 2 SPRING trial in patients with the rare liver disease primary sclerosing cholangitis (PSC). This study reported positive 15-week and 48-week results, achieving the primary safety endpoint and showing improvements on a wide range of disease-related secondary endpoints in nebokitug-treated patients with moderate to advanced disease. Recently, Chemomab reported that the company and the FDA have aligned on a clear regulatory pathway for nebokitug for the treatment of PSC, positioning nebokitug to potentially become the first FDA-approved therapy for this devastating disease that lacks effective treatments. The plan calls for a single Phase 3 pivotal trial with a primary endpoint consisting of a composite of clinical events associated with disease progression in PSC. Neither liver biopsies nor confirmatory studies are required. Derisking data from the SPRING trial suggests that treatment with nebokitug has the potential to positively impact the number and timing of clinical events. Preparations for the Phase 3 trial are ongoing as Chemomab continues discussions with potential strategic partners. Nebokitug also has shown potential as a treatment for systemic sclerosis (SSc) and the SSc program has an open U.S. IND.